Novo Nordisk's September Test: Pipeline Payments and Profit Guidance Collide With Structural Doubts
Published on 09/03/2026 at 09:23 | Editorial boerse-global.de
The Danish pharmaceutical heavyweight finds itself in an unusual position as the calendar edges toward late September: operational metrics are improving, partnership milestones are being hit, and yet the equity continues to trade with a persistent discount that suggests the market is looking past the near term.
A fresh tranche of collaboration revenue landed at the end of August when US partner Lexicon Pharmaceuticals confirmed receipt of a second milestone payment worth $10 million from Novo Nordisk. The trigger was the achievement of required initial dosing levels in a Phase-1 study for LX9851, an oral inhibitor of Acyl-CoA synthetase 5 that Novo Nordisk is licensing for obesity and related metabolic conditions. Lexicon has indicated a third milestone payment of the same magnitude could arrive before year-end. The Phase-1 trial, which evaluates ascending single and multiple doses against placebo in overweight and obese subjects, was initiated back in March and represents one strand of Novo Nordisk's broader effort to diversify beyond its established Ozempic and Wegovy franchises.
A Stock Caught Between Upgrades and Downgrades
The analyst community remains visibly fractured over the shares' direction. JPMorgan lifted its price target on August 25 from 250 to 275 Danish kroner while keeping a Neutral stance, citing a 5 percent upward revision to its 2026 revenue forecast. The bank's reasoning centered on milder-than-expected revenue erosion from generic competition targeting Ozempic, alongside more favorable US pricing concessions than previously modeled.
That constructive read stands in stark contrast to the bearish camp. Berenberg had already cut the stock from Buy to Hold on August 17, trimming its target from $50 to $47 on expectations of intensifying rivalry in the oral weight-loss pill arena — a battleground where Novo Nordisk and Eli Lilly are increasingly going head-to-head. Deutsche Bank went further still, issuing a Sell recommendation on August 27 with a price objective of 265 Danish kroner, pointing to an anticipated growth deceleration in 2027, pipeline setbacks — most notably the late-stage failure of the cardiovascular candidate Ziltivekimab — and substantial patent cliff exposure later in the decade.
The conflicting signals leave the stock hovering in a technical no-man's-land. In pre-market trading, the shares were indicated around €40.26, roughly 27 percent beneath the 52-week high of €54.86 reached in January. Year-to-date losses stand at 8.6 percent, widening to 17 percent on a twelve-month view. A recent session did see the equity advance 3.5 percent to €40.34, but that bounce arrived without any identifiable catalyst — a development that arguably raises more questions than it answers. The shares now sit a marginal 0.4 percent above their 200-day moving average while remaining 3.3 percent below the 50-day line, with a relative strength index near 50 underscoring the prevailing indecision.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The Operating Picture Tells a Different Story
Beneath the choppy price action, the underlying business has demonstrated more resilience than some bears anticipated. Second-quarter results showed currency-adjusted revenues climbing 7 percent, with adjusted operating profit advancing 11 percent. Reported sales reached 78.49 billion kroner, and the oral Wegovy formulation is now contributing a meaningful 3.22 billion kroner to the top line.
Management responded by tightening its full-year guidance in early August. Rather than the previous scenario of adjusted revenues declining as much as 4 percent on constant exchange rates, the company now sees a range from a 6 percent contraction to flat performance. The same improved band applies to adjusted operating profit. That revision suggests the feared erosion from copycat products has so far proven more moderate than originally anticipated — a theme JPMorgan explicitly incorporated into its target increase.
The US Question Lingers
Yet for all the guidance optimism, a significant caveat remains embedded in the outlook. Novo Nordisk is guiding toward a decline in its US business, driven by softer prescription trends for injectable GLP-1 therapies, heightened competitive pressure, and reduced Medicaid reimbursement for obesity medications. That the company's most important market is showing signs of softening is a factor that arguably tempers the improved guidance more than the recent share-price stabilization would suggest.
Management has been leaning on shareholder returns to buttress confidence. The ongoing buyback program has seen nearly 31 million B-shares repurchased since early February at an average price of 281.08 kroner, representing roughly 8.7 billion kroner in transactions. The program is slated to run until early February 2027 with a ceiling of up to 11.2 billion kroner. Such repurchases provide technical support for the equity, though they do little to address the fundamental questions around growth durability.
London Awaits
All roads now lead to September 21, when Novo Nordisk hosts its Capital Markets Day in London. Management is expected to present fresh strategic objectives alongside a comprehensive review of its research pipeline and operational trajectory. That gathering will offer the clearest opportunity yet for the company to mount a credible response to the structural criticisms leveled by Deutsche Bank and echoed by other skeptics — the softening US franchise, the pipeline disappointments, and the looming patent expirations.
Until then, the equity appears destined to oscillate between two competing narratives: one of near-term operational stabilization supported by improving guidance and partnership progress, and another of longer-term competitive vulnerability that no amount of buyback activity can fully dispel. With the shares still roughly a quarter below their peak and carrying a negative year-to-date return, the burden of proof rests squarely on the company to demonstrate that its growth story retains genuine momentum — or concede that the skeptics have been reading the tea leaves correctly all along.
Ad
Novo Nordisk Stock: New Analysis - 3 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
